Dizal Pharma
Shanghai, China· Est.
A clinical-stage biopharma developing novel, global small molecule drugs for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A clinical-stage biopharma developing novel, global small molecule drugs for oncology and immunology.
OncologyImmunology
Technology Platform
Utilizes structure-based drug design and translational medicine to develop selective small molecule inhibitors for well-validated oncology and immunology targets.
Opportunities
Significant market opportunity if its lead candidates demonstrate superior clinical profiles in large oncology indications like NSCLC.
Risk Factors
Clinical and regulatory risks in late-stage trials, plus intense competition in its core therapeutic areas.
Competitive Landscape
Competes directly with large global pharma and biotechs in targeted oncology (e.g., AstraZeneca in EGFR) by aiming for best-in-class profiles.